155 related articles for article (PubMed ID: 26899763)
1. HER-2, ER, PR status concordance in primary breast cancer and corresponding metastatic lesion in lymph node in Chinese women.
Li MH; Hou CL; Wang C; Sun AJ
Pathol Res Pract; 2016 Apr; 212(4):252-7. PubMed ID: 26899763
[TBL] [Abstract][Full Text] [Related]
2. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.
Zhao S; Xu L; Liu W; Lv C; Zhang K; Gao H; Wang J; Ma R
Int J Clin Exp Pathol; 2015; 8(5):5744-8. PubMed ID: 26191291
[TBL] [Abstract][Full Text] [Related]
4. Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases.
Desouki MM; Atta IS; Wolff DJ; Self SE
Turk Patoloji Derg; 2016; 32(3):178-85. PubMed ID: 27562392
[TBL] [Abstract][Full Text] [Related]
5. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
6. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.
Curtit E; Nerich V; Mansi L; Chaigneau L; Cals L; Villanueva C; Bazan F; Montcuquet P; Meneveau N; Perrin S; Algros MP; Pivot X
Oncologist; 2013 Jun; 18(6):667-74. PubMed ID: 23723333
[TBL] [Abstract][Full Text] [Related]
7. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis.
Ba JL; Liu CG; Jin F
Asian Pac J Cancer Prev; 2014; 15(21):9233-9. PubMed ID: 25422206
[TBL] [Abstract][Full Text] [Related]
8. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
[TBL] [Abstract][Full Text] [Related]
9. Expression of Hypoxia-Inducible Factor 1α in Invasive Breast Cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and EPO-R.
Badowska-Kozakiewicz A; Sobol M; Patera J
Adv Clin Exp Med; 2016; 25(4):741-50. PubMed ID: 27629849
[TBL] [Abstract][Full Text] [Related]
10. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
11. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760
[TBL] [Abstract][Full Text] [Related]
12. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment.
Liu J; Deng H; Jia W; Zeng Y; Rao N; Li S; Jin L; Wu J; Song E; Su F
J Cancer Res Clin Oncol; 2012 May; 138(5):837-42. PubMed ID: 22290394
[TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma.
Peiró G; Adrover E; Aranda FI; Peiró FM; Niveiro M; Sánchez-Payá J
Am J Clin Pathol; 2007 May; 127(5):780-6. PubMed ID: 17439837
[TBL] [Abstract][Full Text] [Related]
16. Comparison of estrogen receptors, progesterone receptors and HER-2/neu expression between primary and metastatic breast carcinoma.
Azam M; Qureshi A; Mansoor S
J Pak Med Assoc; 2009 Nov; 59(11):736-40. PubMed ID: 20361669
[TBL] [Abstract][Full Text] [Related]
17. Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor.
Macfarlane R; Seal M; Speers C; Woods R; Masoudi H; Aparicio S; Chia SK
Oncologist; 2012; 17(2):172-8. PubMed ID: 22267852
[TBL] [Abstract][Full Text] [Related]
18. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
19. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
Bauer K; Parise C; Caggiano V
BMC Cancer; 2010 May; 10():228. PubMed ID: 20492696
[TBL] [Abstract][Full Text] [Related]
20. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]